SCHEMBL20697220

SCHEMBL20697220

CCNc1cccnc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.45
GRM5 P41594 1/20 0.44
SLC22A12 Q96S37 1/20 0.43
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
APLNR P35414 1/20 0.41
POLB P06746 1/20 0.39
EDNRA P25101 1/20 0.38
KDM1A O60341 3/20 0.38
MAOA P21397 1/20 0.38
PGK1 P00558 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAOB P27338 1/20 0.38
BTK Q06187 1/20 0.37
PDE1A P54750 1/20 0.37
PDE1B Q01064 1/20 0.37
PDE1C Q14123 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10830144 0.86 PDE5A (0.45) IDO1SLC22A12SLC6A2SLC6A4APLNR
SCHEMBL21258513 0.83 IDO1 (0.41) IDO1GRM5POLBL3MBTL1ALDH1A1
SCHEMBL17700350 0.81 SLC22A12 (0.40) IDO1SLC22A12SLC6A2SLC6A4APLNR
SCHEMBL21246154 0.81 MKNK2 (0.44) IDO1GRM5SLC6A2SLC6A4POLB
SCHEMBL28608817 0.80 SLC22A12 (0.48) SLC22A12APLNRPOLBBTKMEN1
SCHEMBL28608816 0.80 SLC22A12 (0.42) SLC22A12APLNRKDM1AL3MBTL1BTK
SCHEMBL3904232 0.79 SLC22A12 (0.46) GRM5SLC22A12APLNRPOLBKDM1A
SCHEMBL23583163 0.77 IDO1 (0.42) IDO1GRM5SLC6A2SLC6A4POLB
SCHEMBL19002820 0.77 SLC6A2 (0.46) IDO1GRM5SLC6A2SLC6A4L3MBTL1
SCHEMBL22593335 0.77 SLC22A12 (0.44) GRM5SLC22A12APLNRKDM1AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022117016-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 深圳微芯生物科技股份有限公司 2022-06-09 WO disclosed
US-11046698-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-06-29 US disclosed
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 US disclosed
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 US disclosed
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-31 US disclosed
CN-102574845-A 1h-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG 2012-07-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046698-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 IDO1 429/4885GRM5 3233/4885SLC22A12 4652/4885
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 IDO1 429/4885GRM5 3233/4885SLC22A12 4652/4885
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 IDO1 429/4885GRM5 3233/4885SLC22A12 4652/4885
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 IDO1 429/4885GRM5 3233/4885SLC22A12 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.